PCM
PBYI icon

Perkins Capital Management’s Puma Biotechnology PBYI Stock Holding History

Perkins Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Buy
13,400
+900
+7% +$6.59K 0.08% 72
2026
Q1 		$79.9K Hold
12,500
– – 0.07% 80
2025
Q4 		$74.4K Buy
12,500
+300
+2% +$1.59K 0.06% 86
2025
Q3 		$64.8K Buy
+12,200
New +$51.7K 0.06% 80

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perkins Capital Management's PBYI Position: Q2 2026 in Review

Perkins Capital Management increased its Puma Biotechnology (PBYI) stake by 7.2% in Q2 2026, buying an estimated $6.59K and bringing the position to 13,400 shares worth $109K. The position accounts for 0.08% of the portfolio, ranked #72.

Perkins Capital Management first reported a position in PBYI in Q3 2025 and has held it in 4 quarters since. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Perkins Capital Management held 13,400 shares of Puma Biotechnology worth $109K as of Q2 2026.
  • Perkins Capital Management bought 900 Puma Biotechnology shares in Q2 2026, an estimated $6.59K.
  • Puma Biotechnology made up 0.08% of Perkins Capital Management's portfolio in Q2 2026, its #72 holding.
  • Perkins Capital Management first reported a position in Puma Biotechnology in Q3 2025 and has held it in 4 quarters since.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.